Data from Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis Article Swipe
Rachel Offenbacher
,
Kyle W. Jackson
,
Masanori Hayashi
,
Jinghang Zhang
,
Da Peng
,
Yuqi Tan
,
Tracy Murray Stewart
,
Paul Ciero
,
Jackson R. Foley
,
Robert A. Casero
,
Patrick Cahan
,
David M. Loeb
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.8065172
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.c.8065172
Purpose:Despite decades of clinical trials, no progress has been made in improving the survival of patients with Ewing sarcoma who either present with metastatic disease or suffer a metastatic relapse. In our preclinical models, we found differential levels of polyamines in tumors that metastasize compared with tumors that do not, leading us to investigate the potential for D,L-α-difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, to prevent Ewing sarcoma metastasis.Experimental Design:The effect of DFMO on Ewing sarcoma cell lines in vitro was studied by measuring proliferation, sphere formation, and clonogenic growth in soft agar. The effect in vivo was investigated using our orthotopic implantation/amputation model of metastasis. Transcriptomic changes were evaluated by RNA sequencing.Results:DFMO causes a cell cycle arrest and inhibits both sarcosphere formation and clonogenic growth in soft agar. In vivo, DFMO slows primary tumor growth and inhibits metastasis. RNA sequencing demonstrated gene expression patterns consistent with induction of ferroptosis caused by polyamine depletion, which was validated in vitro by demonstrating that DFMO treatment induces lipid peroxidation, and ferrostatin-1 and liproxstatin-1 allow sphere formation even in the presence of DFMO.Conclusions:DFMO slows the growth of Ewing sarcoma cells in vitro, with a profound impact on sphere formation and clonogenic growth, and affects all aspects of Ewing sarcoma tumorigenesis, including tumor initiation, tumor growth, and metastasis, probably through induction of ferroptosis mediated by polyamine depletion. Our results provide preclinical justification to test the ability of DFMO to prevent metastatic recurrence in patients with Ewing sarcoma.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.c.8065172
- OA Status
- gold
- OpenAlex ID
- https://openalex.org/W4414708885
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414708885Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.c.8065172Digital Object Identifier
- Title
-
Data from Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing FerroptosisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-10-01Full publication date if available
- Authors
-
Rachel Offenbacher, Kyle W. Jackson, Masanori Hayashi, Jinghang Zhang, Da Peng, Yuqi Tan, Tracy Murray Stewart, Paul Ciero, Jackson R. Foley, Robert A. Casero, Patrick Cahan, David M. LoebList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.c.8065172Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.c.8065172Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W4414708885 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.c.8065172 |
| ids.doi | https://doi.org/10.1158/1078-0432.c.8065172 |
| ids.openalex | https://openalex.org/W4414708885 |
| fwci | 0.0 |
| type | article |
| title | Data from Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T13157 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.993399977684021 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1312 |
| topics[0].subfield.display_name | Molecular Biology |
| topics[0].display_name | Cancer-related gene regulation |
| topics[1].id | https://openalex.org/T11924 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9926000237464905 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Polyamine Metabolism and Applications |
| topics[2].id | https://openalex.org/T10269 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.975600004196167 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Epigenetics and DNA Methylation |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.c.8065172 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.c.8065172 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5009545770 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5211-6457 |
| authorships[0].author.display_name | Rachel Offenbacher |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Rachel Offenbacher |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5000526521 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3398-7548 |
| authorships[1].author.display_name | Kyle W. Jackson |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kyle W. Jackson |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5045599016 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9508-0159 |
| authorships[2].author.display_name | Masanori Hayashi |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Masanori Hayashi |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5029774267 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-1436-6460 |
| authorships[3].author.display_name | Jinghang Zhang |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Jinghang Zhang |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5011893957 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5782-8405 |
| authorships[4].author.display_name | Da Peng |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Da Peng |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5041761505 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7200-3222 |
| authorships[5].author.display_name | Yuqi Tan |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Yuqi Tan |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5073262248 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8679-6414 |
| authorships[6].author.display_name | Tracy Murray Stewart |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Tracy Murray Stewart |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5027761503 |
| authorships[7].author.orcid | https://orcid.org/0009-0000-5199-9270 |
| authorships[7].author.display_name | Paul Ciero |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Paul Ciero |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5076986853 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4383-9522 |
| authorships[8].author.display_name | Jackson R. Foley |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jackson Foley |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5076964907 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-5653-3306 |
| authorships[9].author.display_name | Robert A. Casero |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Robert A. Casero |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5004108540 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-3652-2540 |
| authorships[10].author.display_name | Patrick Cahan |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Patrick Cahan |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5034420962 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-7319-5000 |
| authorships[11].author.display_name | David M. Loeb |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | David M. Loeb |
| authorships[11].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.c.8065172 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13157 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.993399977684021 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1312 |
| primary_topic.subfield.display_name | Molecular Biology |
| primary_topic.display_name | Cancer-related gene regulation |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.c.8065172 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.8065172 |
| primary_location.id | doi:10.1158/1078-0432.c.8065172 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.c.8065172 |
| publication_date | 2025-10-01 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 27, 114, 190 |
| abstract_inverted_index.In | 30 |
| abstract_inverted_index.an | 59 |
| abstract_inverted_index.by | 82, 110, 151, 159, 220 |
| abstract_inverted_index.do | 48 |
| abstract_inverted_index.in | 10, 40, 90, 126, 175, 238 |
| abstract_inverted_index.no | 5 |
| abstract_inverted_index.of | 2, 14, 38, 61, 71, 104, 148, 178, 183, 203, 217, 232 |
| abstract_inverted_index.on | 73, 193 |
| abstract_inverted_index.or | 25 |
| abstract_inverted_index.to | 52, 64, 228, 234 |
| abstract_inverted_index.us | 51 |
| abstract_inverted_index.we | 34 |
| abstract_inverted_index.Our | 223 |
| abstract_inverted_index.RNA | 111, 139 |
| abstract_inverted_index.The | 93 |
| abstract_inverted_index.all | 201 |
| abstract_inverted_index.and | 87, 118, 123, 136, 167, 169, 196, 199, 212 |
| abstract_inverted_index.for | 56 |
| abstract_inverted_index.has | 7 |
| abstract_inverted_index.our | 31, 100 |
| abstract_inverted_index.the | 12, 54, 176, 181, 230 |
| abstract_inverted_index.was | 80, 97, 155 |
| abstract_inverted_index.who | 19 |
| abstract_inverted_index.DFMO | 72, 131, 162, 233 |
| abstract_inverted_index.been | 8 |
| abstract_inverted_index.both | 120 |
| abstract_inverted_index.cell | 76, 115 |
| abstract_inverted_index.even | 174 |
| abstract_inverted_index.gene | 142 |
| abstract_inverted_index.made | 9 |
| abstract_inverted_index.not, | 49 |
| abstract_inverted_index.soft | 91, 127 |
| abstract_inverted_index.test | 229 |
| abstract_inverted_index.that | 42, 47, 161 |
| abstract_inverted_index.were | 108 |
| abstract_inverted_index.with | 16, 22, 45, 146, 189, 240 |
| abstract_inverted_index.Ewing | 17, 66, 74, 184, 204, 241 |
| abstract_inverted_index.agar. | 92, 128 |
| abstract_inverted_index.allow | 171 |
| abstract_inverted_index.cells | 186 |
| abstract_inverted_index.cycle | 116 |
| abstract_inverted_index.found | 35 |
| abstract_inverted_index.lines | 77 |
| abstract_inverted_index.lipid | 165 |
| abstract_inverted_index.model | 103 |
| abstract_inverted_index.slows | 132, 180 |
| abstract_inverted_index.tumor | 134, 208, 210 |
| abstract_inverted_index.using | 99 |
| abstract_inverted_index.which | 154 |
| abstract_inverted_index.arrest | 117 |
| abstract_inverted_index.caused | 150 |
| abstract_inverted_index.causes | 113 |
| abstract_inverted_index.effect | 70, 94 |
| abstract_inverted_index.either | 20 |
| abstract_inverted_index.growth | 89, 125, 135, 182 |
| abstract_inverted_index.impact | 192 |
| abstract_inverted_index.levels | 37 |
| abstract_inverted_index.sphere | 85, 172, 194 |
| abstract_inverted_index.suffer | 26 |
| abstract_inverted_index.tumors | 41, 46 |
| abstract_inverted_index.(DFMO), | 58 |
| abstract_inverted_index.ability | 231 |
| abstract_inverted_index.affects | 200 |
| abstract_inverted_index.aspects | 202 |
| abstract_inverted_index.changes | 107 |
| abstract_inverted_index.decades | 1 |
| abstract_inverted_index.disease | 24 |
| abstract_inverted_index.growth, | 198, 211 |
| abstract_inverted_index.induces | 164 |
| abstract_inverted_index.leading | 50 |
| abstract_inverted_index.models, | 33 |
| abstract_inverted_index.present | 21 |
| abstract_inverted_index.prevent | 65, 235 |
| abstract_inverted_index.primary | 133 |
| abstract_inverted_index.provide | 225 |
| abstract_inverted_index.results | 224 |
| abstract_inverted_index.sarcoma | 18, 67, 75, 185, 205 |
| abstract_inverted_index.studied | 81 |
| abstract_inverted_index.through | 215 |
| abstract_inverted_index.trials, | 4 |
| abstract_inverted_index.clinical | 3 |
| abstract_inverted_index.compared | 44 |
| abstract_inverted_index.inhibits | 119, 137 |
| abstract_inverted_index.mediated | 219 |
| abstract_inverted_index.patients | 15, 239 |
| abstract_inverted_index.patterns | 144 |
| abstract_inverted_index.presence | 177 |
| abstract_inverted_index.probably | 214 |
| abstract_inverted_index.profound | 191 |
| abstract_inverted_index.progress | 6 |
| abstract_inverted_index.relapse. | 29 |
| abstract_inverted_index.survival | 13 |
| abstract_inverted_index.evaluated | 109 |
| abstract_inverted_index.formation | 122, 173, 195 |
| abstract_inverted_index.improving | 11 |
| abstract_inverted_index.including | 207 |
| abstract_inverted_index.induction | 147, 216 |
| abstract_inverted_index.inhibitor | 60 |
| abstract_inverted_index.measuring | 83 |
| abstract_inverted_index.polyamine | 62, 152, 221 |
| abstract_inverted_index.potential | 55 |
| abstract_inverted_index.treatment | 163 |
| abstract_inverted_index.validated | 156 |
| abstract_inverted_index.clonogenic | 88, 124, 197 |
| abstract_inverted_index.consistent | 145 |
| abstract_inverted_index.depletion, | 153 |
| abstract_inverted_index.depletion. | 222 |
| abstract_inverted_index.expression | 143 |
| abstract_inverted_index.formation, | 86 |
| abstract_inverted_index.metastatic | 23, 28, 236 |
| abstract_inverted_index.orthotopic | 101 |
| abstract_inverted_index.polyamines | 39 |
| abstract_inverted_index.recurrence | 237 |
| abstract_inverted_index.sequencing | 140 |
| abstract_inverted_index.synthesis, | 63 |
| abstract_inverted_index.<i>In | 129 |
| abstract_inverted_index.<i>in | 78, 95, 157, 187 |
| abstract_inverted_index.ferroptosis | 149, 218 |
| abstract_inverted_index.initiation, | 209 |
| abstract_inverted_index.investigate | 53 |
| abstract_inverted_index.metastasis, | 213 |
| abstract_inverted_index.metastasis. | 105, 138 |
| abstract_inverted_index.metastasize | 43 |
| abstract_inverted_index.preclinical | 32, 226 |
| abstract_inverted_index.sarcosphere | 121 |
| abstract_inverted_index.demonstrated | 141 |
| abstract_inverted_index.differential | 36 |
| abstract_inverted_index.investigated | 98 |
| abstract_inverted_index.demonstrating | 160 |
| abstract_inverted_index.ferrostatin-1 | 168 |
| abstract_inverted_index.justification | 227 |
| abstract_inverted_index.peroxidation, | 166 |
| abstract_inverted_index.Transcriptomic | 106 |
| abstract_inverted_index.liproxstatin-1 | 170 |
| abstract_inverted_index.proliferation, | 84 |
| abstract_inverted_index.tumorigenesis, | 206 |
| abstract_inverted_index.vivo</i> | 96 |
| abstract_inverted_index.vitro</i> | 79, 158 |
| abstract_inverted_index.vivo</i>, | 130 |
| abstract_inverted_index.vitro</i>, | 188 |
| abstract_inverted_index.Design:<p>The | 69 |
| abstract_inverted_index.implantation/amputation | 102 |
| abstract_inverted_index.D,L-α-difluoromethylornithine | 57 |
| abstract_inverted_index.sarcoma.</p></div> | 242 |
| abstract_inverted_index.metastasis.</p>Experimental | 68 |
| abstract_inverted_index.DFMO.</p>Conclusions:<p>DFMO | 179 |
| abstract_inverted_index.sequencing.</p>Results:<p>DFMO | 112 |
| abstract_inverted_index.<div>AbstractPurpose:<p>Despite | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 12 |
| citation_normalized_percentile.value | 0.44408873 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |